scholarly journals Inhibition of leukotriene B4-induced CD11B/CD18 (Mac-1) expression by BIIL 284, a new long acting LTB4 receptor antagonist, in patients with rheumatoid arthritis

2004 ◽  
Vol 63 (2) ◽  
pp. 170-176 ◽  
Author(s):  
R Alten
Keyword(s):  
Rheumatoid Arthritis ◽  
Receptor Antagonist ◽  
Leukotriene B4 ◽  
Long Acting ◽  
Ltb4 Receptor

Tc-99m-labeled Leukotriene-B4 (LTB4) receptor antagonist RP517 for scintigraphic imaging of infection

2000 ◽  
Vol 21 (6) ◽  
pp. 585-586
Author(s):  
A. H. Brouwers ◽  
P. Laverman ◽  
O. C. Boerman ◽  
W. J.G. Oyen ◽  
J. A. Barrett ◽  
...  
Keyword(s):  
Receptor Antagonist ◽  
Leukotriene B4 ◽  
Scintigraphic Imaging ◽  
Imaging Of Infection ◽  
Ltb4 Receptor

scholarly journals The Leukotriene B4 Receptor Antagonist ONO-4057 Inhibits Nephrotoxic Serum Nephritis in WKY Rats

1999 ◽  
Vol 10 (2) ◽  
pp. 264-270
Author(s):  
SATORU SUZUKI ◽  
TAKESHI KURODA ◽  
JUN-ICHIROU KAZAMA ◽  
NAOFUMI IMAI ◽  
HIDEKI KIMURA ◽  
...  
Keyword(s):  
Receptor Antagonist ◽  
Crescentic Glomerulonephritis ◽  
Leukotriene B4 ◽  
Dependent Manner ◽  
Wistar Kyoto ◽  
Leukotriene B4 Receptor ◽  
Phosphate Buffered Saline ◽  
Dose Dependent ◽  
Ltb4 Receptor

Abstract. To evaluate the role of leukotriene B4 (LTB4) in glomerulonephritis, this study was conducted to examine whether ONO-4057, an LTB4 receptor antagonist, moderated nephritis caused by the injection of nephrotoxic serum (NTS) into Wistar-Kyoto rats. Rats were given intraperitoneal injections of ONO-4057 or phosphate-buffered saline 24 h before the injection of NTS. These rats subsequently received equal doses of ONO-4057 or phosphate-buffered saline 3 h and 1, 2, 3, 4, 5, and 6 d later. Compared with the control groups, ONO-4057 treatment significantly reduced proteinuria and hematuria, suppressed the glomerular accumulation of monocytes/macrophages, and reduced the formation of crescentic glomeruli in a dose-dependent manner. These results suggest that LTB4 is responsible for the crescentic formations and renal dysfunction associated with NTS nephritis. The LTB4 receptor antagonist ONO-4057 may thus be beneficial in the treatment of crescentic glomerulonephritis.

The effect of tocilizumab - an interleukin-6 receptor antagonist - on lipid levels in rheumatoid arthritis

2017 ◽  
Author(s):  
Ifigenia Kostoglou-Athanassiou ◽  
Lambros Athanassiou ◽  
Aikaterini Tzanavari ◽  
Charoula Katsavouni ◽  
Markos Kostopoulos ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Receptor Antagonist ◽  
Interleukin 6 ◽  
Lipid Levels ◽  
Interleukin 6 Receptor

scholarly journals AB0308 NO SIGNS OF CONGESTIVE HEART DISEASE PROGRESSION IN PATIENTS WITH RHEUMATOID ARTHRITIS ON IL-6 RECEPTOR ANTAGONIST AFTER 12 MONTHS TREATMENT

2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 1452.3-1453
Author(s):  
A. Martynova ◽  
T. Popkova ◽  
H. Gerasimova
Keyword(s):  
Rheumatoid Arthritis ◽  
Heart Disease ◽  
Receptor Antagonist ◽  
Disease Progression ◽  
European Heart Journal ◽  
Heart Function ◽  
Clinical Signs ◽  
Left Ventricular ◽  
Ultrasound Evaluation ◽  
Congestive Heart Disease

Background:N-terminal pro-brain natriuretic peptide (NT-proBNP) is a known marker of heart dysfunction, mainly described in patients with high activity of rheumatoid arthritis (RA). Further knowledge of the influence of the IL-6 receptor antagonist, tocilizumab (TCZ), on NT-proBNP levels and systolic heart function is yet to be obtained.Objectives:Access the effect of 12 months TCZ therapy on NT-proBNP levels, transthoracal ehocardiography results and analyze the association between congestive heart disease progression and RA activity.Methods:37 RA patients (pts) (31F/6M); median age 56,5 [48; 63,5] years; disease duration 48 [6; 348] months; DAS28 score 6,15 [5,44; 6,45]; rheumatoid factor (RF)+100%; anti–citrullinated protein antibody (ACPA) + 79,6% were treated in an open-label study with TCZ (8 mg/kg every 4 weeks). Identification of NT-pro-BNT in blood serum, transthoracal ultrasound evaluation of left ventriculum ejection fraction (LVEF), E/A ratio performed at baseline and 12 months.Results:11 (29,7%) pts had congestive heart disease (CHD) (II functional class of NYHA), 7 (18,9%) pts having signs of mild left ventricular dysfunction (LVD) as dyspnea, shortness of breath, cardiotropic treatment remained the same in the course of the study. After 12 month TCZ treatment as RA activity lowered (DAS28 2.32 [1,75; 3,15], р<0,05), NT-proBNP levels decreased (100,95 [57.9; 117.6] pg/ml to 90,46 [33.62; 106.6] pg/ml), along with elevation of LVEF (60,75 [60; 70]% to 67,68 [62.5; 73.5], p = 0,001). Increase of E/A (0,97 [0.8; 1.17] to 1,04 [0.7; 1.42] correlated with decrease of NT-proBNP level (r = -0,63, p=0,036). Raise of LVEF over 12 months correlated with decrease of RA activity according to SDAI scale (r= -0,670, p<0,05). No significant relationship between NT-proBNP levels, LVEF, E/A and other scales measuring RA activity was found. Clinically all patients had improvement in evaluation of their health and no signs of CHD or RVD progression were found.Conclusion:Use of TCZ in patients with active RA showed none to positive influence on heart condition, specifically, lowering NT-proBNP levels, improving LVEF and reducing clinical signs of LVD.References:[1]Pan Y, Li D, Ma J, Shan L, Wei M. NT-proBNP test with improved accuracy for the diagnosis of chronic heart failure. Medicine (Baltimore). 2017 Dec;96(51):e9181.[2]D Novikova, I Kirillova, E Markelova et al. The first report of significantly improvement of NT-proBNP level in rheumatoid arthritis patients treated with tofacitinib during 12-month follow-up, European Heart Journal, Volume 40, Issue Supplement_1, October 2019, ehz745.0836.[3]Pappas DA, Nyberg F, Kremer JM et al. Clin Rheumatol. 2018 Sep;37(9):2331-2340.Disclosure of Interests:None declared

ChemInform Abstract: The Synthesis of an Aminohexyl-Containing Analogue of the Chromanol Leukotriene B4 Receptor Antagonist CP-195543: A Scaffold for the Preparation of Derivatized Analogues.

ChemInform ◽  
2000 ◽  
Vol 31 (47) ◽  
pp. no-no
Author(s):  
Brian P. Jones ◽  
Klaas Schildknegt ◽  
Kathyrn F. Wright ◽  
Henry J. Showell ◽  
James P. Dittami ◽  
...  
Keyword(s):  
Receptor Antagonist ◽  
Leukotriene B4 ◽  
Leukotriene B4 Receptor

Effect of leukotriene B4 receptor antagonist (ONO4057) on hepatic allografting in rats

2000 ◽  
Vol 32 (7) ◽  
pp. 2340 ◽  
Author(s):  
M Tanaka ◽  
T Tamaki ◽  
Y Konoeda ◽  
Y Uchida ◽  
T Kaizu ◽  
...  
Keyword(s):  
Receptor Antagonist ◽  
Leukotriene B4 ◽  
Leukotriene B4 Receptor
Sign in / Sign up

Export Citation Format

Share Document